Abstract #0135

T1 is a biomarker of therapy-induced cell death in the Th-MYCN genetically-engineered murine model of neuroblastoma.

Yann Jamin¹, Evon S.C. Poon², Albert Hallsworth², Hannah Webber², Laura S. Danielson², Dow-Mu Koh¹, Louis Chesler², and Simon P. Robinson¹

¹Division of Radiotherapy & Imaging, The Institute of Cancer Research, London, United Kingdom, ²Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, United Kingdom

In this study we demonstrate that T₁ provides a non-invasive biomarker of response to MLN8237, a potent Aurora A kinase inhibitor, in the Th-MYCN genetically-engineered murine model of neuroblastoma, a childhood cancer of the nervous system. Histopathological characterisation demonstrates that T₁ is a generic biomarker of cell death in this model. T₁ quantification in pediatric early-phase clinical trials could potentially help to accelerate the development of urgently needed novel targeted therapies for children with neuroblastoma.

This abstract and the presentation materials are available to members only; a login is required.

Join Here